Platelet Storage Pool Disease Medical Services in China

Platelet Storage Pool Disease (PSPD) is a rare inherited or acquired bleeding disorder characterized by quantitative or qualitative deficiencies in platelet granules—specifically alpha-granules, dense granules, or both. These granules store critical mediators of hemostasis, including adenosine diphosphate (ADP), serotonin, calcium, fibrinogen, von Willebrand factor, and platelet-derived growth factors. In PSPD, defective granule biogenesis, trafficking, or secretion impairs platelet activation, aggregation, and clot stabilization, leading to mucocutaneous bleeding manifestations. Pathogenically, inherited forms are typically autosomal recessive and linked to mutations in genes such as NBEAL2 (causing gray platelet syndrome), GFI1B, RAB27B, or AP3B1; acquired variants may arise secondary to myelodysplastic syndromes, chronic myeloid leukemia, or certain drug exposures (e.g., chloroquine, valproic acid). Epidemiologically, PSPD is exceedingly rare, with an estimated prevalence of fewer than 1 in 1,000,000 individuals globally; precise incidence remains undefined due to underdiagnosis and phenotypic overlap with other platelet function disorders like Bernard-Soulier syndrome or Glanzmann thrombasthenia. Risk factors include consanguineous parentage (for autosomal recessive forms), underlying hematologic malignancies, prolonged exposure to granule-toxic medications, and coexisting autoimmune conditions. Clinical presentation commonly includes easy bruising, epistaxis, menorrhagia, gingival bleeding, and prolonged bleeding after minor trauma or surgery—though severity varies widely, from asymptomatic to life-threatening hemorrhage. Importantly, routine coagulation tests (PT, aPTT, platelet count) are typically normal, necessitating specialized diagnostics: light transmission aggregometry (showing impaired response to ADP, epinephrine, and collagen), electron microscopy (revealing absent or sparse granules), flow cytometry for granule membrane markers (e.g., CD63 for dense granules, P-selectin for alpha-granules), and genetic testing when indicated. Quality of life is significantly impacted: patients often experience anxiety around surgical procedures, limitations in physical activity or sports participation, recurrent medical visits, and psychosocial burden related to unpredictable bleeding episodes—particularly affecting adolescents and women of childbearing age due to menstrual and obstetric risks. While not curable, management focuses on prophylaxis and acute bleeding control, requiring multidisciplinary coordination between hematologists, gynecologists, anesthesiologists, and dental specialists. Long-term monitoring for clonal evolution (especially in acquired cases) is essential, as some subtypes carry increased risk of myeloid neoplasms.

Platelet Storage Pool Disease (PSPD) is a heterogeneous group of inherited or acquired platelet function disorders characterized by quantitative or qualitative deficiencies in platelet granules—primarily dense granules (δ-storage pool deficiency), alpha granules (α-storage pool deficiency, often overlapping with gray platelet syndrome), or combined defects. Patients typically present with mild-to-moderate mucocutaneous bleeding—epistaxis, menorrhagia, easy bruising, and prolonged bleeding after surgery or trauma—despite normal platelet counts and routine coagulation screening (PT, aPTT, fibrinogen). Diagnosis requires specialized testing: flow cytometry for mepacrine-labeled dense granules, electron microscopy for ultrastructural granule assessment, and assays of platelet secretion (e.g., ATP release following agonist stimulation with collagen or epinephrine). Genetic testing (e.g., *NBEAL2*, *RAB27A*, *UNC13D*, *AP3B1*) may confirm specific subtypes, particularly in familial cases.

Conservative management forms the cornerstone of PSPD care and is indicated for patients with mild or intermittent symptoms. First-line conservative strategies include meticulous avoidance of antiplatelet agents (e.g., aspirin, NSAIDs, SSRIs), prophylactic dental hygiene to prevent gingival bleeding, and patient education on recognizing early signs of hemorrhage. For minor procedures (e.g., dental extractions, skin biopsies), local hemostatic measures—tranexamic acid mouthwash, fibrin sealants, absorbable gelatin sponge (Gelfoam®), or topical thrombin—are highly effective. Menorrhagia in adolescent and reproductive-age females is managed with hormonal therapy (combined oral contraceptives or levonorgestrel-releasing intrauterine systems), which reduces endometrial proliferation and menstrual blood loss. Iron supplementation is routinely prescribed for iron-deficiency anemia secondary to chronic blood loss; ferritin-guided repletion is standard. In pediatric patients, conservative observation with serial clinical assessments is preferred unless bleeding significantly impairs quality of life or growth.

Pharmacologic interventions are reserved for moderate-to-severe bleeding episodes or perioperative prophylaxis. Desmopressin (DDAVP) remains the most widely used agent, administered intravenously (0.3 mcg/kg) or intranasally (150–300 mcg), and acts by releasing endothelial von Willebrand factor and factor VIII while enhancing platelet adhesion and P-selectin expression. Though response is variable—particularly in δ-SPD where dense granule ATP/ADP stores are depleted—approximately 60–70% of patients demonstrate transient improvement in bleeding time and platelet aggregation. Antifibrinolytics, especially tranexamic acid (10–25 mg/kg orally three times daily for 5–7 days), are first-line adjuncts for mucosal bleeding and surgical prophylaxis due to their inhibition of plasmin-mediated clot lysis. Intravenous immunoglobulin (IVIG) has shown benefit in select cases with immune-mediated secondary PSPD (e.g., post-chemotherapy or autoimmune thrombocytopenia), likely via Fc receptor blockade and modulation of reticuloendothelial clearance. Platelet transfusions are strictly limited to life-threatening hemorrhage or major surgery unresponsive to pharmacologic measures, given risks of alloimmunization, febrile reactions, and transmission of infectious agents. HLA-matched or crossmatched platelets are recommended when transfusion is unavoidable.

Surgical treatment plays no primary role in PSPD pathophysiology but is critically relevant in managing complications or comorbid conditions. Splenectomy is contraindicated—not only does it fail to correct the intrinsic platelet defect, but it increases lifelong risk of overwhelming sepsis and thrombosis without improving bleeding diathesis. However, surgical intervention may be necessary for bleeding-related sequelae: endoscopic ablation or cauterization for refractory epistaxis; hysterectomy or endometrial ablation for intractable menorrhagia unresponsive to medical therapy; or laparoscopic ovarian cystectomy in cases complicated by hemorrhagic ovarian cysts. All surgical planning mandates multidisciplinary coordination between hematologists, anesthesiologists, and surgeons, with preoperative DDAVP and tranexamic acid, intraoperative cell salvage, and meticulous hemostatic technique. Elective procedures should be deferred until optimal hemostatic coverage is achieved.

Treatment advantages in China reflect robust infrastructure, innovation, and integration within the national healthcare system. Major tertiary hospitals—including Peking Union Medical College Hospital, Ruijin Hospital (Shanghai Jiao Tong University), and West China Hospital—offer comprehensive hemostasis laboratories capable of advanced platelet function testing (lumi-aggregometry, flow cytometric granule quantification, whole-exome sequencing). China’s National Rare Diseases Registry facilitates longitudinal data collection and accelerates clinical trial enrollment for novel therapeutics. Domestic biopharmaceutical development has expanded access to high-quality, cost-effective DDAVP and tranexamic acid formulations, with median treatment costs approximately 40–60% lower than in Western markets. Furthermore, China’s standardized Hemophilia Treatment Center (HTC) model—now extended to inherited platelet disorders—ensures coordinated care, genetic counseling, psychosocial support, and 24/7 on-call hematologist coverage. Telehematology platforms enable real-time consultation for regional hospitals, reducing diagnostic delays. Notably, Chinese investigators are pioneering research into gene-editing approaches (e.g., CRISPR-Cas9 correction of *NBEAL2* mutations in induced pluripotent stem cell–derived megakaryocytes), positioning the country at the forefront of future curative strategies.

Recovery and long-term management emphasize proactive, individualized strategies. Patients should maintain a bleeding diary documenting episode frequency, severity, triggers, and response to interventions—valuable for adjusting prophylaxis. Annual hematologic evaluation includes CBC, ferritin, and assessment of bleeding score (ISTH-BAT). Vaccination against encapsulated organisms (pneumococcus, meningococcus, Haemophilus influenzae type B) is mandatory, especially if splenectomized for unrelated indications. Physical activity should be encouraged, with avoidance of contact sports only in patients with recurrent traumatic bleeding or documented severe functional impairment. Psychosocial support is integral: anxiety related to unpredictable bleeding and fertility concerns (particularly in women with menorrhagia-associated anemia) warrant routine screening and referral to clinical psychologists or peer-support networks. Pregnancy requires preconception counseling and trimester-specific hemostatic planning—DDAVP is safe in pregnancy, while tranexamic acid use is off-label but supported by extensive observational data. With appropriate multidisciplinary care, most individuals with PSPD achieve excellent quality of life, near-normal life expectancy, and successful participation in education, employment, and family life.